ArticleCureus2025
An Unusual Complete Response to Immunotherapy in a Locoregional Recurrent Merkel Cell Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine carcinoma. Multimodal treatment is associated with improved locoregional control and survival outcomes. We present the case of an 80-year-old male patient who developed MCC on the left arm. After surgical resection with clear margins and a negative sentinel lymph node biopsy (SLNB), the patient remained under follow-up. Nine months later, local recurrence with left axillary lymph node involvement was diagnosed. An oncologic multidisciplinary team recommended neoadjuvant nivolumab. After completing six cycles of immunotherapy, a radical resection of the tumor on the left upper limb and a complete left axillary lymph node dissection were performed. The final histopathological report showed scar fibrosis with no residual cancer and no lymph node metastasis. MCC exhibits immunological sensitivity, and the use of immune checkpoint inhibitors has revolutionized the treatment of advanced and recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.